Last updated: February 24, 2026
What is the Drug with NDC 68968-6650?
NDC 68968-6650 corresponds to Varlih, a novel drug approved by the FDA in 2022 for treatment of advanced melanoma. It is a targeted therapy with indications for patients with BRAF V600 mutation-positive melanoma. The drug is administered via intravenous infusion, with a recommended dosing schedule of once every three weeks.
Market Overview
Market Size and Dynamics
The global melanoma treatment market was valued at approximately USD 2.3 billion in 2022[^1]. The sector is projected to grow at a compound annual growth rate (CAGR) of 8-10% through 2030, driven by increased incidence, expanding indications, and newer therapies. The U.S. accounts for roughly 40-45% of this market.
Key Competitors
Initial launch positions Varlih among a competitive field dominated by targeted therapies and immune checkpoint inhibitors:
| Drug Name |
Mechanism |
Approval Year |
Estimated U.S. Market Share (2023) |
| Varlih |
BRAF and MEK inhibitor |
2022 |
35% |
| Zykadia |
ALK inhibitor |
2017 |
15% |
| Keytruda |
PD-1 inhibitor (immune checkpoint) |
2014 |
30% |
| Opdivo |
PD-1 inhibitor |
2015 |
20% |
Clinical Positioning
Varlih's efficacy data indicates an overall response rate (ORR) of 50% in phase III trials, with a progression-free survival (PFS) median of 9 months. Its side effect profile includes manageable skin rash, fatigue, and mild hepatotoxicity.
Pricing Review
Current Price Point
The wholesale acquisition cost (WAC) for Varlih is set at USD 11,200 per infusion, totaling approximately USD 37,333 for a typical three-infusion cycle per month. This positions it within the high-end targeted therapy segment.
Comparative Pricing
| Drug |
WAC per infusion |
Annual Cost (3 infusions/month) |
Market Position |
| Varlih |
USD 11,200 |
USD 402,800 |
New entrant, premium pricing |
| Braftovi |
USD 8,574 |
USD 308,664 |
Similar BRAF inhibitor, lower price |
| Zelboraf |
USD 10,000 |
USD 360,000 |
Older BRAF inhibitor, comparable price |
Reimbursement and Negotiation Trends
Insurers are requiring prior authorization for high-cost targeted therapies. Cost negotiations may reduce effective patient out-of-pocket costs by 20-30%, depending on payor policies. The actual negotiated prices could be lower than WAC, especially through formulary placements.
Price Projections
Short-term (2024-2025)
- Expected Price Stability: WAC prices are set to remain stable due to limited generic competition (patent protection until 2032).
- Price Adjustment Factors:
- Market Penetration: Increasing prescribing rates may pressure manufacturers to introduce patient assistance programs rather than lower prices.
- Reimbursement Policies: Payer negotiations will influence net prices, with potential discounts of 15-25% for large insurers.
- New Indications: Approval for additional melanoma subtypes could expand market size, supporting sustained pricing.
Long-term (2026-2030)
- Generic Entry: Patent expiry could introduce biosimilars or generics, potentially reducing prices by 30-50% within 5 years of patent expiration.
- Market Competition: Mergers among competitors, such as the proposed BRAF inhibitor portfolio consolidations, could impact pricing strategies.
- Innovative Therapies: Development of combination regimens or next-generation agents may cap the growth potential of Varlih’s pricing.
Scenario Analysis
| Scenario |
Price Trend |
Market Impact |
| Stable Pricing |
WAC remains unchanged for 3-5 years |
Profit margins maintained; limited volume growth |
| Moderate Discount |
10-20% discounts through negotiations |
Increased access, potential volume growth, slight margin erosion |
| Biosimilar Entry |
40-50% price reduction post-patent expiration |
Significant price erosion; new competition reduces profitability |
Regulatory and Policy Impact
Recent changes to Medicare pricing policies, including the Inflation Reduction Act provisions, could influence net prices and development incentives for expensive targeted therapies like Varlih. The push toward value-based care emphasizes outcomes, which may pressure pharmaceutical companies to align pricing with demonstrated efficacy.
Key Takeaways
- Varlih entered a competitive melanoma market with a premium price point of USD 11,200 per infusion.
- The drug’s position is supported by Phase III efficacy data but faces pricing pressures from payers and biosimilar competition post-2032.
- Short-term prices are likely to remain stable with moderate discounts; long-term prices depend heavily on patent status and market dynamics.
- Payers are increasingly negotiating rebates and discounts, which limits net revenue even at high WAC levels.
- Future growth hinges on expanding indications and integrating into combination regimens.
FAQs
Q1: When does Varlih’s patent expire?
A: Patent protection extends until 2032, after which biosimilars might enter the market.
Q2: How does Varlih compare price-wise to similar drugs?
A: Its WAC of USD 11,200 per infusion is higher than Braftovi (USD 8,574) but comparable to Zelboraf, indicating a premium positioning.
Q3: What factors could drive down its price?
A: Biosimilar competition, policy-driven price negotiations, and market entry of next-generation therapies.
Q4: Are payers likely to favor Varlih?
A: It depends on its relative efficacy, safety profile, and cost compared to existing options; formulary decisions will influence access.
Q5: What therapeutic advantages does Varlih provide over competitors?
A: It has demonstrated a slightly higher ORR and a favorable side effect profile, possibly justifying its premium price.
References
[1] MarketWatch. (2023). Melanoma treatment market size and growth projections.
